Hormones and Cancer

, Volume 1, Issue 1, pp 44–54 | Cite as

Mouse Prostate Cancer Cell Lines Established from Primary and Postcastration Recurrent Tumors

  • Chun-Peng Liao
  • Mengmeng Liang
  • Michael B. Cohen
  • Andrea Flesken-Nikitin
  • Joseph H. Jeong
  • Alexander Y. Nikitin
  • Pradip Roy-BurmanEmail author


The clinical course of prostate cancer is grouped into two broad phases. The first phase, which is the growth of the androgen-dependent cancer (AD-Ca), responds well to androgen depletion treatment while the second phase that could be termed as androgen-depletion-independent cancer (ADI-Ca) does not. We used two separate prostate tumors, one AD-Ca and one ADI-Ca from the conditional Pten deletion mouse model, to generate from each a pair of cell lines. The AD-Ca cell lines (E2 and E4) and the ADI-Ca cell lines (cE1 and cE2) display biallelic deletion at the Pten gene locus, an event which is specific for the prostate epithelium for this mouse model and a fairly similar level of expression of the androgen receptor (AR). The ADI-Ca cell lines (cE series) grow well in the absence of androgen, display increased AR transcription under androgen-deprived environment, and retain the sensitivity to increased proliferation when androgen is supplemented. The AD-Ca cell lines (E series) grow slowly in the absence of androgen and, unlike cE cells, do not show increased AR expression when maintained in the absence of androgen. The detection of epithelial cell markers, such as CK8, CK14, CK18, and E-cadherin in the cE series is conforming with the polygonal epithelial morphology of these cells in culture. The E cells also present mostly polygonal-shaped morphology with a small percent of cells with fibroblastoid morphology and produce little or very low levels of cytokeratins but increased levels of vimentin, Twist, and Slug, the markers known to be associated with epithelial–mesenchymal transition. Each of the cell lines, when inoculated subcutaneously into male or female NOD.SCID mice induced tumors within 8 weeks with 100% incidence. Histopathological examinations of the tumor sections, however, led to noticeable biological differences. The cE series engenders adenocarcinomas, particularly in male hosts, and the E series induces sarcomatoid carcinomas (positively stained for CK8 and AR as well as vimentin expression) in either male or female hosts. These new cell lines are promising models for the elucidation of the androgen metabolism and their role in prostate cancer.


Conditional Pten deletion mouse model of prostate adenocarcinoma Mouse prostate cancer cell lines Androgen-dependent and androgen-depletion-independent prostate cancer Prostate sarcomatoid carcinoma 



Grant support: NIH RO1 CA113392 and NIH RO1 CA59705 (P. Roy-Burman) and NIH RO1 CA96823 (A. Nikitin).

We thank all members of the Roy-Burman Laboratory for assistance in various aspects of this work, especially Lauren Geary for the design of primary sets of Snail and Slug and Erik Haw for genotyping. We also thank Dr. Zongxiang Zhou for his initial contributions to karyotyping analyses.


  1. 1.
    Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308CrossRefPubMedGoogle Scholar
  2. 2.
    Bonkhoff H, Berges R (2009) From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100–112CrossRefGoogle Scholar
  3. 3.
    Roy-Burman P, Tindall DJ, Robins DM et al (2005) Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther 4:4–5PubMedGoogle Scholar
  4. 4.
    Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18–25CrossRefPubMedGoogle Scholar
  5. 5.
    Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550–3555PubMedGoogle Scholar
  6. 6.
    Waltering KK, Helenius MA, Sahu B et al (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141–8149CrossRefPubMedGoogle Scholar
  7. 7.
    Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10:981–991CrossRefPubMedGoogle Scholar
  8. 8.
    Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB (2004) Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11:225–254CrossRefPubMedGoogle Scholar
  9. 9.
    Abate-Shen C, Brown PH, Colburn NH et al (2008) The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila Pa) 1:161–166Google Scholar
  10. 10.
    Trotman LC, Niki M, Dotan ZA et al (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1:385–396CrossRefGoogle Scholar
  11. 11.
    Ma X, Ziel-van der Made AC, Autar B et al (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730–5739CrossRefPubMedGoogle Scholar
  12. 12.
    Zhou Z, Flesken-Nikitin A, Corney DC et al (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889–7898CrossRefPubMedGoogle Scholar
  13. 13.
    Bruxvoort KJ, Charbonneau HM, Giambernardi TA et al (2007) Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67:2490–2496CrossRefPubMedGoogle Scholar
  14. 14.
    Wang S, Gao J, Lei Q et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209–221CrossRefPubMedGoogle Scholar
  15. 15.
    Liao CP, Zhong C, Saribekyan G et al (2007) Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67:7525–7533CrossRefPubMedGoogle Scholar
  16. 16.
    van Bokhoven A, Varella-Garcia M, Korch C et al (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205–225CrossRefPubMedGoogle Scholar
  17. 17.
    Navone NM, Olive M, Ozen M et al (1997) Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493–2500PubMedGoogle Scholar
  18. 18.
    Chen ME, Lin SH, Chung LW, Sikes RA (1998) Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 273:17618–17625CrossRefPubMedGoogle Scholar
  19. 19.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y (2009) Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate (in press)Google Scholar
  20. 20.
    Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57:3325–3330PubMedGoogle Scholar
  21. 21.
    Jiao J, Wang S, Qiao R et al (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67:6083–6091CrossRefPubMedGoogle Scholar
  22. 22.
    Choi J, Burns AA, Williams RM et al (2007) Core–shell silica nanoparticles as fluorescent labels for nanomedicine. J Biomed Opt 12:1–12Google Scholar
  23. 23.
    Wu X, Wu J, Huang J et al (2001) Generation of a prostate epithelial cell specific Cre transgenic mouse model for tissue specific gene ablation. Mech Dev 101:61–69CrossRefPubMedGoogle Scholar
  24. 24.
    Leong KG, Wang BE, Johnson L, Gao WQ (2008) Generation of a prostate from a single adult stem cell. Nature 456:804–808CrossRefPubMedGoogle Scholar
  25. 25.
    Nagy A, Gertsenstein M, Vintersten K, Behringer R (2003) Manipulating the mouse embryo. A laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p 389Google Scholar
  26. 26.
    Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I (2007) Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67:1761–1769CrossRefPubMedGoogle Scholar
  27. 27.
    Zhou Z, Flesken-Nikitin A, Nikitin AY (2007) Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 67:5683–5690CrossRefPubMedGoogle Scholar
  28. 28.
    Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S (2007) Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67:5789–5797CrossRefPubMedGoogle Scholar
  29. 29.
    Tran CP, Lin C, Yamashiro J, Reiter RE (2002) Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 1:113–121PubMedGoogle Scholar
  30. 30.
    Hansel DE, Herawi M, Montgomery E, Epstein JI (2007) Spindle cell lesions of the adult prostate. Mod Pathol 20:148–158CrossRefPubMedGoogle Scholar
  31. 31.
    Shappell SB, Thomas GV, Roberts RL et al (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270–2305CrossRefPubMedGoogle Scholar
  32. 32.
    Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39CrossRefPubMedGoogle Scholar
  33. 33.
    Yuan X, Li T, Wang H et al (2006) Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169:682–696CrossRefPubMedGoogle Scholar
  34. 34.
    He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y (2009) Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20:765–776CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Chun-Peng Liao
    • 1
  • Mengmeng Liang
    • 1
  • Michael B. Cohen
    • 3
  • Andrea Flesken-Nikitin
    • 4
  • Joseph H. Jeong
    • 2
  • Alexander Y. Nikitin
    • 4
  • Pradip Roy-Burman
    • 1
    Email author
  1. 1.Department of PathologyUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Department of Molecular Microbiology and Immunology, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  3. 3.Department of PathologyThe University of IowaIowa CityUSA
  4. 4.Department of Biomedical SciencesCornell UniversityIthacaUSA

Personalised recommendations